All therapiesEvidence snapshot 2026-09-13
Weight & glucose

TG103 (efmedaglutide alfa)

Activates GLP-1 receptors. The GLP-1 component is joined to an Fc protein to prolong its action.

GLP-1s & metabolic therapies

At a glance

Selected evidence in this atlas
Studied use & population

Chinese adults with overweight or obesity without diabetes

Study context
Approval & development

Efmedaglutide alfa (TG103/TJ103): China obesity BLA accepted October 2025; second BLA for type 2 diabetes accepted June 2026. No marketing approval verified.

Status sourceStatus & indications
Selected efficacy evidence

6.47% reported weight loss · 1.76% loss with placebo · 12 weeks

TG103 phase 1b MAD · Phase 1b · peer-reviewed · 30 mg once weekly · Other / incompletely specified

Evidence & limitations
Important safety context

Most reported adverse events were mild or moderate gastrointestinal events.

Safety context
Next milestone

A next milestone is not summarized for this therapy.

Milestone details

Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.

Evidence in the atlas

1 result

Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.

Weight loss

TG103 phase 1b MAD

6.47% reported weight loss · 1.76% loss with placebo · 12 weeks

30 mg once weekly

Chinese adults with overweight or obesity without diabetes

Least-squares mean percent change at D85. Efmedaglutide alfa (TG103/TJ103): China obesity BLA accepted October 2025; second BLA for type 2 diabetes accepted June 2026. No marketing approval verified.

Safety context

Most reported adverse events were mild or moderate gastrointestinal events.

Limitations: Old small phase 1b result; later phase 3 development; highest dose selected, not 15 mg arm with largest observed loss. No mandated lifestyle intervention.

Explore result Compare study Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection · 2024-05

Biology & identity

Status in this atlas: Efmedaglutide alfa (TG103/TJ103): China obesity BLA accepted October 2025; second BLA for type 2 diabetes accepted June 2026. No marketing approval verified. Status source

Hormone activity

GLP-1Activates receptors

Activates GLP-1 receptors. The GLP-1 component is joined to an Fc protein to prolong its action.

What do these hormones do? GLP-1

No approved trade name verified. Efmedaglutide alfa is the generic name; TG103 and TJ103 are development codes. Filing acceptance is not marketing approval.

TJ Biopharma · Current licensor; succeeded I-Mab's licensing position following restructuring in April 2024.; CSPC Pharmaceutical Group / CSPC Baike · Exclusive Mainland-China development, registration, manufacturing and commercialization partner.; I-Mab Biopharma · Historical licensor in the original 2018 CSPC agreement; current licensor is TJ Biopharma.

Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.

The molecule

Activates GLP-1 receptors. The GLP-1 component is joined to an Fc protein to prolong its action.
Structure not yet verified

Structure not verified

Activates GLP-1 receptors. The GLP-1 component is joined to an Fc protein to prolong its action.

Shown: Protein drug / fusion construct

An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.

TG103 (efmedaglutide alfa)

Development timeline

Next milestone

A next milestone is not summarized for this therapy. This does not mean development has ended.

Development history3 selected milestones

TG103 (efmedaglutide alfa) · compound history across indications

Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.

  1. Licensor changes after restructuring

    TJ Biopharma became the licensor under the pre-existing CSPC agreement, retaining future milestones and royalties.

    Source

  2. Obesity BLA acceptance announced

    TJ Biopharma announced that NMPA accepted CSPC Baike's filing for long-term management of overweight or obese adults.

    Source

  3. Diabetes BLA acceptance announced

    A second Chinese filing was accepted, for glycemic control in adults with type 2 diabetes.

    Source

Selected sources checked Sep 13, 2026. This is not an exhaustive history.